Overview

Study to Compare the Combination of Ribociclib Plus Goserelin Acetate With Hormonal Therapy Versus Combination Chemotherapy in Premenopausal or Perimenopausal Patients With Advanced or Metastatic Breast Cancer

Status:
Recruiting

Trial end date:
2022-12-31

Target enrollment:

Participant gender:

Summary

To compare the combination of Ribociclib plus goserelin acetate with hormonal therapy versus combination chemotherapy in premenopausal or perimenopausal patients with advanced or metastatic breast cancer

Phase:

Phase 2

Details

Lead Sponsor:

Novartis Pharmaceuticals

Treatments:

Albumin-Bound Paclitaxel
Anastrozole
Capecitabine
Docetaxel
Gemcitabine
Goserelin
Letrozole
Paclitaxel
Vinblastine
Vinorelbine